Clinical trialNCT06518837RecruitingPhase 2Interventional

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

SponsorRutgers, The State University of New JerseyEnrollment40HER2-Negative Breast CancerHormone Receptor-Positive Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), changes in BMI and body fat distribution, metabolic markers, and circulating tumor DNA (ctDNA).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Coral Omene, MD., PhD
Rutgers Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Trinitas Comprehensive Cancer Center
Elizabeth, New Jersey, United States
Recruiting
Rwj Barnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton, New Jersey, United States
Not, yet, recruiting
Rwjbarnabas Health - Cooperman Barnabas, Livingston
Livingston, New Jersey, United States
Recruiting
Rwjbarnabas Health - Monmouth Medical Center
Long Branch, New Jersey, United States
Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey, United States
Recruiting
Rwjbarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, United States
Recruiting
Rwj Barnabas Health - Robert Wood Johnson University Hospital, Somerset
Somerville, New Jersey, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tirzepatide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Oct 2024
Primary completion: 30 Sept 2027
Completion: 30 Sept 2027
Last update posted: 21 Jan 2026
Registered enrollment: 40
Registry id: NCT06518837

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.